Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Fair value upgrade for ASX listed fast food chain
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Wide moat airport share steps up its investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,364.10 | 39.60 | 0.42% |
| CAC 40 | 8,453.01 | 31.42 | -0.37% |
| DAX 40 | 26,106.60 | 29.96 | -0.11% |
| Dow JONES (US) | 53,417.16 | 140.15 | 0.26% |
| FTSE 100 | 10,854.32 | 37.76 | 0.35% |
| HKSE | 25,517.33 | 492.13 | -1.89% |
| NASDAQ | 25,980.19 | 200.27 | -0.76% |
| Nikkei 225 | 64,980.48 | 547.61 | -0.84% |
| NZX 50 Index | 13,932.71 | 50.83 | 0.37% |
| S&P 500 | 7,652.86 | 21.51 | -0.28% |
| S&P/ASX 200 | 9,155.40 | 45.10 | 0.50% |
| SSE Composite Index | 3,882.00 | 0.01 | -0.00% |